SOURCE: The Rosen Law Firm, P.A.

September 01, 2005 18:30 ET

Notice of Filing Securities Class Action Against Immucor, Inc., Dr. Gioacchino De Chirico, Steven C. Ramsey and Edward L. Gallup

NEW YORK, NY -- (MARKET WIRE) -- September 1, 2005 -- The Rosen Law Firm (http://www.rosenlegal.com) announced today it has filed a class action lawsuit on behalf of purchasers of Immucor, Inc. (NASDAQ: BLUD) ("Immucor'' or the "Company'') publicly traded securities during the period between January 7, 2005 and August 29, 2005 (the "Class Period''), against defendants Immucor and certain of its current and former officers and directors.

If you purchased or otherwise acquired BLUD common stock between January 7, 2005 and August 29, 2005, and suffered losses in your investment, you may request that the Court appoint you as lead plaintiff no later than fifty-nine days from today. Any member of the class may move the Court to serve as lead plaintiff in this action through counsel of his or her choice, or may remain an absent class member. There are certain legal requirements to serve as lead plaintiff, which the Rosen Law Firm would be happy to discuss with you. You may contact the firm by contacting Laurence Rosen, Esq. at lrosen@rosenlegal.com or by calling toll-free at 866-767-3653. You are also welcome to submit questions or transaction information to the Rosen Law Firm online at www.rosenlegal.com

A copy of the Complaint filed in this action is available at www.rosenlegal.com or by emailing lrosen@rosenlegal.com. You can also obtain the complaint from the US District Courthouse in Atlanta, GA, where the case is pending.

The Complaint alleges that defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") by misrepresenting that Immucor's financial statements and disclosures fairly and accurately reflected the Company's results of operations as required by Generally Accepted Accounting Principles ("GAAP") and the Exchange Act. The Complaint also charges that Defendants' Sarbanes-Oxley certifications during the Class Period were false and misleading, as the Company, knowingly or with severe recklessness, lacked adequate internal controls and failed to keep proper books and records in violation of their well-publicized Code of Corporate Conduct.

On August 26, 2005 the Company announced that the Securities and Exchange Commission (the "SEC") had launched a formal investigation into payments made by its Italian unit and its president, Defendant De Chirico, in October 2003 to a physician connected with a hospital with which the Company was doing business. After the market closed on August 29, 2005, the Company revealed further that its Chief Financial Officer had resigned, that it would be revising its previously issued results for at least two quarters in order to account for a previously unrecorded accrued bonus, and that its Form 10-K for fiscal year 2005 would be further delayed due to additional accounting and auditing procedures the Company claimed was necessary to properly reflect the accrued bonus and to render the internal controls report required by Section 404 of Sarbanes Oxley.

As a result of the alleged fraud, the price of Immucor common stock dropped from a closing price of $28.61 on August 25, 2005 before the market learned of the SEC's formal investigation to close at $24.00 per share on August 30, 2005.

If you wish to discuss your rights or interests regarding this class action, please contact plaintiff's counsel, Laurence Rosen, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at lrosen@rosenlegal.com

Contact Information